First Synthesis of N-(4-Fluorophenyl)-5-(4-fluorophenyl)-2-(4-hydroxybenzyl)pentanamide, a New Potential Cholesterol Absorption Inhibitor

doi:10.1111/J.2042-7158.2000.TB00212.X

Paper

First Synthesis of N-(4-Fluorophenyl)-5-(4-fluorophenyl)-2-(4-hydroxybenzyl)pentanamide, a New Potential Cholesterol Absorption Inhibitor

Published 2000 · J. Guillon, S. Stiebing, M. Robba

Pharmacy and Pharmacology Communications

UNKNOWN SJR score

1

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

The first synthesis of N-(4-fluorophenyl)-5-(4-fluorophenyl)-2-(4-hydroxybenzyl)pentanamide and a new synthesis of 1-(4-fluorophenyl)-3-[(4-fluorophenyl)propyl]-4-(4-hydroxyphenyl)-2-azetidinone starting from 4-fluorobenzaldehyde are described. This new amide could represent a potential new cholesterol absorption inhibitor.

Study Snapshot

N-(4-fluorophenyl)-5-(4-fluorophenyl)-2-(4-hydroxybenzyl)pentanamide shows potential as a new cholesterol absorption inhibitor, with its synthesis starting from 4-fluorobenzaldehyde.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Paper

First Synthesis of N-(4-Fluorophenyl)-5-(4-fluorophenyl)-2-(4-hydroxybenzyl)pentanamide, a New Potential Cholesterol Absorption Inhibitor

References

Citations

Kinetics and mechanism of the base-catalyzed rearrangement and hydrolysis of ezetimibe.

Base-catalyzed hydrolysis of ezetimibe produces complex products with complex pH-rate profiles, involving specific base catalysis and no buffer catalysis.